ArticleTheranostics2021
Establishment and prospective validation of an SUV
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Meta-analysis ofCancer imaging : the official publication of the International Cancer Imaging Society · 2023Pooled it
- Does previous transurethral resection of the prostate negatively influence subsequent robotic-assisted radical prostatectomy in men diagnosed with prostate cancer? A systematic review and meta-analysis.Journal of robotic surgery · 2023Pooled it
- Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.Prostate cancer and prostatic diseases · 2026Article
- Diagnostic impact of interpretation criteria for [European journal of nuclear medicine and molecular imaging · 2026Article
- The value of [Quantitative imaging in medicine and surgery · 2026Article
- Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- The feasibility of [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Construction and external validation of radiomics models to detect primary prostate cancer with machine learning: a multicenter study based onJournal of the National Cancer Center · 2026Article
- IntegratedEJNMMI research · 2026Article
- Impact of local tumor-to-background uptake ratio on PET metabolic response assessment.Radiation protection dosimetry · 2026Article
- Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).Theranostics · 2026Review
- PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making.Abdominal radiology (New York) · 2026Review
- Context-level machine learning to improve the identification of lymph node and bone metastases in prostate cancer patients using [EJNMMI physics · 2025Article
- The role of PSMA PET/CT in identifying benign and malignant intracranial lesions in patients with prostate cancer.Clinical imaging · 2025Article
- Prostate cancer misdiagnosed as prostatic abscess: case report and literature review.BMC urology · 2025Review
- Impact ofDiagnostics (Basel, Switzerland) · 2025Article
- Combination of prostate cancer antigen 3 (PCA3), sarcosine, glypican-1 (GPC1), urokinase plasminogen activator receptor (uPAR), and thymidine kinase 1 (TK1), and T2WI and DWI radiomics model for distinguishing benign prostatic hyperplasia, prostate cancer, and prostatitis.Journal of medical biochemistry · 2025Article
- Development and validation of a visual nomogram for predicting clinically significant prostate cancer in negative mpMRI usingScientific reports · 2025Article
- Which patients with negative PSMA-PET imaging can safely avoid biopsy for prostate cancer? a novel step towards PSMA-based biopsy-free strategy.European journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.